Login    Join free Add to favorites    中文
Home > News > Agilent Expands Cell Analysis R&D Capabilities in Ireland
Industry Updates New Products Supplier News Upcoming Events business web
Agilent Expands Cell Analysis R&D Capabilities in Ireland
hits:185     Date:12/28/18

New facility incorporates recently acquired Luxcel Biosciences
 
Agilent Technologies Inc. (NYSE: A) today announced the opening of a new, purpose-built extension to its Little Island, Cork facility in Ireland. The campus will focus on developing advanced technologies for the analysis of live-cells in real-time.
 
The expanded state-of-the-art facility incorporates recently acquired Luxcel Biosciences, adding real-time, fluorescence plate reader-based in vitr.
 
Agilent entered the cell analysis market in 2015 with the acquisition of Seahorse Bioscience, a leader in the development of specialized instruments and live-cell, kinetic assays. The addition of Luxcel expands Agilent's cell analysis portfolio and brings new capabilities through technology and research which will drive advancements in this fast-evolving field for Agilent globally.
 
"Technological progression allowing researchers to examine cell health and function kinetically, and in real-time, are driving global demand for complete cell analysis solutions," said Todd Christian, general manager, Agilent Cell Analysis Division. "The Luxcel acquisition and Agilent Ireland expansion underscore Agilent's continued commitment to the growing cell analysis market."
 

 
"We're excited that Agilent has invested in Ireland," said Martin Shanahan, chief executive officer, IDA Ireland. "Luxcel has partnerships and active research programs in Ireland, and with major EU and UK research institutions. This expansion will not only provide the most up-to-date and advanced solutions for Agilent's customers but will have a significant positive impact within the Irish and European innovation ecosystem."
 
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenues of $4.47 billion in fiscal 2017 and employs 14,500 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to our Newsroom.
Related News>> more
advertisement
Copyright(C) 2006-2019 Bio-Equip    E-mail:web@bio-equip.cn   娌狪CP澶06040519鍙